On July 28,2014,FDA issued an important final guidance relating to the Agency's substantive review of 510(k) notifications,entitled "The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]."  This guidance applies to the 510(k) review process for both diagnostic and therapeutic devices and is applicable to 510(k) reviews undertaken by the Center for … Continue Reading